Pharmacologic management of nonalcoholic fatty liver disease

Clinics in Liver Disease

Volumn 8, Issue 3, 2004, Pages 715-728

  Harrison, Stephen A ^a   Neuschwander Tetri, Brent A ^b  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ATORVASTATIN; BETAINE; BIGUANIDE; CLOFIBRATE; GEMFIBROZIL; METFORMIN; PIOGLITAZONE; PROBUCOL; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; URSODEOXYCHOLIC ACID;

CLINICAL FEATURE; CLINICAL TRIAL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PHLEBOTOMY; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT REDUCTION;

ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; ANTIOXIDANTS; APPETITE DEPRESSANTS; FATTY LIVER; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; URSODEOXYCHOLIC ACID; WEIGHT LOSS;

EID: 4344629342     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2004.04.011     Document Type: Review

References (75)

1. Marchesini G., Brizi M., Marsell-Labate A.M., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 107:1999;450-455
2. Sanyal A.J., Campbell-Sangert C., Mirshahi F., et al. Nonalcohlic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 120:2001;1183-1192
3. Kopelman P.G. Obesity as a medical problem. Nature. 404:2000;635-643
4. Boyle J.P., Honeycutt A.A., Narayan K.M., et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the US. Diabetes Care. 24:2001;1936-1940
5. Harrison S.A., Diehl A.M. Fat and the liver - a molecular overview. Semin Gastrointest Dis. 13:2002;3-16
6. Lee R.G. Nonalcoholic steatohepatitis: a study of 39 patients. Hum Pathol. 20:1989;594-598
7. Powell E.E., Cooksley W.G., Hanson R., et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 11:1990;74-80
8. Bacon B.R., Farahvash M.J., Janney C.G., et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 107:1994;1103-1109
9. Willner I.R., Waters B., Raj Patil S., et al. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol. 96:2001;2957-2961
10. Bugianesi E., Leone N., Vanni E., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 123:2002;134-140
11. Ong J.P., Younossi Z.M. Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis? Gastroenterology. 123:2002;375-378
12. Ludwig J., Viggiano T.R., McGIll D.B., et al. Nonalcoholic steatohepatitis: Mayo Clinic experience with a hitherto unnamed disease. Mayo Clin Proc. 55:1980;434-438
13. Harrison S.A., Hayashi P. Clinical factors associated with fibrosis in 102 patients with nonalcoholic steatohepatitis. Hepatology. 36:2002;412A
14. Angulo P., Keach J.C., Batts K.P., et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 30:1999;1356-1362
15. Chitturi S., Weltman M., Farrell G.C., et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology. 36:2002;142-149
16. Lebovitz H.E. The relationship of obesity to the metabolic syndrome. Int J Clin Pract. 134:2003;18-27
17. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 37:2003;917-923
18. Thompson P.D., Crouse S.F., Goodpaster B., et al. The acute versus the chronic response to exercise. Med Sci Sports Exerc. 33(6 Suppl):2001;S438-S445
19. Scheen A.J., Luyckx F.H. Obesity and liver disease. Best Prac Res Clin Endocrinol Metab. 16:2002;703-716
20. Zhou G., Myers R., Li Y., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 108:2001;1167-1174
21. Day C., James O. Steatohepatitis: a tale of two "hits"? [editorial]. Gastroenterology. 114:1998;842-845
22. Palmer M., Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology. 99:1990;1408-1413
23. Ueno T., Sagawara H., Sujaka K., et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol. 27:1997;103-107
24. Rozental P., Biava C., Spencer H., et al. Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis. 12:1967;198-208
25. Anderson T., Gluud C., Franzmann M.B., et al. Hepatic effects of dietary weight loss in morbidly obese patients. J Hepatol. 12:1991;224-229
26. Luyckx F.H., Scheen A.J., Desaive C., Thiry A., Lefebvre P.J. Parallel reversibility of biological markers of the metabolic syndrome and liver steatosis after gastroplasty-induced weight loss in severe obesity. J Clin Endocrinol Metab. 84:1999;4293
27. Heck A.M., Yanovski J.A., Calis K.A. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy. 20:2000;270-279
28. Harrison S.A., Ramrakhiani S., Brunt E.M., Anbari M.A., Cortese C., Bacon B.R. Orlistat in the treatment of NASH: a case series. Am J Gastroenterol. 98:2003;926-930
29. Harrison S.A., Fincke C., Helinski D., et al. Orlistat treatment in obese, nonalcoholic steatohepatitis patients: a pilot trial. Hepatology. 36:2002;406A
30. Musso G., Gambino R., De Michieli F., Cassader M., Rizzetto M., Durazzo M., et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology. 37:2003;909-916
31. Laurin J., Lindor K.D., Crippen J.S., et al. Ursodeoxycholic acid or clofibrate in the treatment of nonalcohol-induced steatohepatitis: a pilot study. Hepatology. 23:1996;1464-1467
32. Basaranoglu M., Acbay O., Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol. 31:1999;384
33. Horlander J.C., Kwo P.Y., Cummings O.W. Atorvastatin for the treatment of NASH. Gastroenterology. 120:2001;A544
34. Merat S., Malekzadeh R., Sohrabi M.R., Hormazdi M., Naserimoghadam S., Mikaeli J., et al. Probucol in the treatment of nonalcoholic steatohepatitis: an open-labeled study. J Clin Gastroenterol. 36:2003;266-268
35. Lehmann J.M., Moore L.B., Smith-Oliver T.A., et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator- activated receptor gamma (PPAR gamma). J Biol Chem. 270:1995;12953-12956
36. Mayerson A.B., Hundal R.S., Dufour S., et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 51:2002;797-802
37. Fryer L.G.D., Parbu-Patel A., Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem. 277:2002;25226-25232
38. Kim Y.-B., Ciaraldi T.P., Kong A., et al. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110β protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes. 51:2002;443-448
39. Galli A., Crabb D.W., Cerri E., et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology. 122:2002;1924-1940
40. Caldwell S.H., Hespenheide E.E., Redick J.A., Iezzoni J.C., Battle E.H., Sheppard B.L. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol. 96:2001;519-525
41. Menon K.V.N., Angulo P., Lindor K.D. Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. Am J Gastroenterol. 96:2001;1631-1634
42. Neuschwander-Tetri B.A., Isley W.L., Oki J.C., Ramrakhiani S., Quiason S.G., Phillips N.J., et al. Troglitazone-induced hepatic failure leading to liver transplantation. Ann Intern Med. 129:1998;38-41
43. Shadid S., Jensen M.D. Effect of pioglitazone on biochemical indices of nonalcoholic fatty liver disease in upper body obesity. Clin Gastro Hepatol. 1:2003;384-387
44. Acosta R.C., Molina E.G., O'Brien C.B., Cobo M.C., Amaro R., Neff G.W., et al. The use of pioglitazone on nonalcohlic steatohepatitis [abstract]. Gastroenterology. 120(Suppl):2001;A546
45. Sanyal A.J., Contos M.J., Sargeant C., Stravitz R.T., Luketic V.A., Sterling R.K., et al. A randomized controlled pilot study of pioglitazone and vitamin E versus vitamin E for nonalcoholic steatohepatitis [abstract]. Hepatology. 36(Suppl):2002;382A
46. Promrat K., Lutchman G., Kleiner D.E., Uwaifo G.I., Freedman R.J., Soza A., et al. Pilot study of pioglitazone in nonalcoholic steatohepatitis [abstract]. Gastroenterology. 124(Suppl):2003;A708
47. Neuschwander-Tetri B.A., Brunt E.M., Wehmeiher K.R., Oliver D., Bacon B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology. 38:2003;1008-1017
48. Neuschwander-Tetri B.A., Brunt E.M., Wehmeiher K.R., Sponseller C., Hampton K., Bacon B.R. Interim results of a pilot study demonstrating the early effects of the PPAR-γ ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol. 38:2003;434-440
49. Lin H.Z., Yang S., Chuckaree C., et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med. 6:2000;998-1003
50. Marchesini G., Brizi M., Blanchi G., et al. Metformin in non-alcoholic steatohepatitis. Lancet. 358:2001;893-894
51. Nair S., Diehl A.M., Perrillo R. Metformin in non alcoholic steatohepatitis (NASH): efficacy and safety: a preliminary report. Gastroenterology. 1222:2002;A621
52. Bataller R., Sancho-Bru P., Gines P., Lora J.M., Al-Garawi A., Sole M., et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology. 125:2003;117-125
53. Yoshiji H., Kuriyama S., Fukui H. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol. 23:2002;348-356
54. Wei H., Lu H., Li D., Zhan Y., Wang Z., Huang X. The expression of AT1 receptor on hepatic stellate cells in rat fibrosis induced by CCl4. Chinese Med J. 114:2001;583-587
55. Harrison S.A., DiBisceglie A.M. Advances in the understanding and treatment of nonalcoholic fatty liver disease. Drugs. 63:2003;1-17
56. Phung N., Farrell G., Robertson G. Vitamin E but not glutathione precursors inhibits hepatic fibrosis in experimental NASH exhibiting oxidative stress and mitochondrial abnormalities. Hepatology. 34:2001;361A
57. Parola M., Leonarduzzi G., Biasi F., et al. Vitamin E dietary supplementation protects against carbon tetrachloride-induced chronic liver damage and cirrhosis. Hepatology. 16(4):1992;1014-1021
58. Parola M., Muraca R., Dianzani I., et al. Vitamin E dietary supplementation inhibits tissue growth factor beta-1 gene expression in the rat liver. FEBS Lett. 308:1992;267-270
59. Lavine J.E. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr. 136:2000;734-738
60. Hasegawa T., Yoneda M., Nakamura K., et al. Plasma transforming growth factor-1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther. 15:2001;1667-1672
61. Harrison S.A., Torgerson S., Hayashi P., et al. Vitamin E and vitamin C in the treatment of nonalcoholic steatohepatitis. Am J Gastroenterol. 98:2003;2485-2490
62. Lu S.C. S-adenosylmethionine. Int J Biochem Cell Bio. 32:2000;391-395
63. Mato J.M., Camara J., Ortiz P., et al. Spanish collaborative group for the study of alcoholic liver cirrhosis. S-adenosylmethionine in the treatment of alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind multicenter clinical trial. J Hepatol. 30:1999;1081-1089
64. Abdelmalek M.F., Angulo P., Jorgensen R.A., et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol. 96:2001;2711-2717
65. Miglio F., Rovati L.C., Santoro A., Setkikar I. Eficacy and safety of oral betaine glucuronate in nonalcoholic steatohepatitis. Arzneim-Forsch./Drug Res. 50:2000;722-727
66. Desai T.K. Phlebotomy reduces transaminase levels in patients with chronic non-viral non-alcoholic steatohepatitis. Hepatology. 24(Suppl):1996;1498A
67. Desai T.K. Phlebotomy reduces transaminase levels in patients with non-alcoholic steatohepatitis [abstract]. Gastroenterology. 118:2000;A1071
68. Nitecki J., Jackson F.W., Allen M.L., et al. Effect of phlebotomy on non-alcoholic steatohepatitis (NASH) [abstract]. Gastroenterology. 118:2000;A6679
69. Facchini F.S., Hua N.W., Stoohs R.A. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology. 122:2002;931-939
70. Gulbahar O., Karasu Z.A., Ersoz G., Akarca U.S., Musoglu A. Treatment of non-alcoholic steatohepatitis with N-acetylcysteine. Gastroenterology. 118(Suppl):2000;A6550
71. Angulo P., Lindor K.D. Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis. 21:2001;81-88
72. Laurin J., Lindor K.D., Crippen J.S., et al. Ursodeoxycholic acid or clofibrate in the treatment of nonalcohol-induced steatohepatitis: a pilot study. Hepatology. 23:1996;1464-1467
73. Ceriani R., Bunati S., Morini L., et al. Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis. Hepatology. 28:1998;386A
74. Guma G., Viola L., Thome M., et al. Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis:results of a prospective clinical controlled trial. Hepatology. 26:1997;387A
75. Lindor K.D. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis:results of a randomized, placebo-controlled trial. Hepatology. 39:2004;770-778